Travere Therapeutics, Inc. (TVTX) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Heavy leverage ⢠Volatile cashflow TVTX shows strong liquidity and very high gross margins but is undermined by heavy leverage, oversized operating expenses causing fiscal losses, and stretched valuation .
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠RSI near-oversold ⢠Support at $27.2â$27.8 Support Level: $27.20â$27.80 Resistance Level: $28.90; $30.70â$30.90 Trading below its last-month SMA (~$28.90) with RSI â31 near oversold; support $27.20â$27.80 must hold or a break implies further weakness, while clearing $28.90 and the $30.70â$30.90 cluster is needed to resume an uptrend.
Sentiment & News
Key News Insights: ⢠FILSPARI adoption ⢠FSGS PDUFA April ⢠Returned to profitability Travere posted strong FY25 results with 81% revenue growth driven by FILSPARI, returned to GAAP profitability, advanced its IgAN/FSGS/HCU programs (PDUFA for FSGS in April) but the stock slipped on low-volume selling.
AI Summary
Travere has shifted from a binary clinical bet to a commercial-growth story anchored on FILSPARI momentum and improving quarterly cash generation, but that upside is highly conditional on a favorable FSGS PDUFA and the company converting adoption into durable margins while managing heavy leverage. Monitor the PDUFA outcome, published grossâtoânet trends, and consecutive quarterly positive free cash flow over the next 2â4 quartersâfailure on any of these will likely trigger sharp repricing or dilution.
Description
Travere Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases. Its marketed portfolio includes treatments for bile acid disorders and a drug for cystinuria, while its pipeline comprises a Phase III program for kidney diseases and an investigational enzyme-replacement candidate for classical homocystinuria. The company conducts partnered research with the NIH and patient organizations on rare genetic conditions, was renamed from Retrophin in 2020, and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | TVTX | Travere Therapeutics, Inc. | Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally. | Closed | -2.0% |